The average one-year price target for Bionano Genomics (BMV:BNGO) has been revised to MX$100.98 / share. This is an increase of 21.14% from the prior estimate of MX$83.36 dated September 13, 2026.

TXG begins Atera shipments as orders top 40 systems, highlighting strong early demand and broad research interest in its ...

The average one-year price target for 10x Genomics (NASDAQGS:TXG) (LSE:0A88) has been revised to $60.62 / share. This is an increase of 13.66% from the prior estimate of $53.33 dated September 11, ...

Veracyte has acquired Convergent Genomics in a transaction valued at up to $180 million, adding the UroAmp urinary tumor DNA ...

PRNewswire/ -- (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, ...

Cancer genomics is the study of the totality of DNA sequence and gene expression differences between tumour cells and normal host cells. It aims to understand the genetic basis of tumour cell ...

AI is accelerating genomic analysis, drug discovery, precision medicine and CRISPR, creating opportunities in multi-omics, generative AI, diagnostics and industry partnerships.Dublin, Sept. (GLOBE ...

The era of predictive genomics is rapidly reshaping how we think about disease, risk and lifelong health. Recent advances in whole-genome sequencing have equipped clinicians with insights into our ...

Introduced in April of this year, Atera brings together whole transcriptome analysis, sub-cellular resolution, single cell ...

Agreement strengthens Sai Life Sciences' discovery and development platforms with access to foundational CRISPR/Cas9 intellectual property, enabling responsible innovation and enhanced global partner ...

For decades, cancer treatment has largely followed a one-size-fits-all approach: the same chemotherapy regimen given to every ...

Origin Genomics aims to prove the potential benefits of its technology for editing disease-causing genes in human embryos ...